


Understanding Vesicoureteral Reflux (VUR)

What is VUR?

VUR occurs when the ureter opening located at the joining of the ureter and the bladder does not close properly. This causes urine to flow back up (reflux) from the bladder to the ureters and eventually to the kidneys.




How does a healthy kidney, ureter and bladder function?

- Urine normally flows in one direction: down from the kidneys, through the ureters, to the bladder
- The urine is stored in the bladder until urination occurs
- Urine is released from the bladder and flows out of the body through the urethra


What conditions are associated with VUR?

- Urinary tract infection (UTI) is associated with VUR
- Some children with VUR and febrile UTI have an increased risk of developing renal (kidney) scars
- Renal scars suggest that areas of renal damage exist, which may have been present from birth, or may have occurred due to other causes such as a kidney infection, called pyelonephritis


Healthy Bladder (empty)




Healthy Bladder (with urine)



Anatomy of VUR (with urine)



Anatomy of VUR (with urine)



Grade 1	Grade 2	Grade 3	Grade 4	Grade 5

Grades of VUR

What is Deflux®?

Deflux is a gel made from two naturally occurring sugars, hyaluronic acid and dextranomer, and is indicated for treatment of VUR. A paediatric urologist injects Deflux in or around the ureter opening (where the ureter joins the bladder). Deflux has been used safely and effectively for over 20 years, showing up to 93% success rates after one treatment.¹

Will VUR resolve on its own?

The percent chance of reflux resolution after specified number of years [95% confidence interval]^{2*}

RISK CATEGORY	1 YEAR	2 YEARS	3 YEARS	4 YEARS	5 YEARS
age in months; number of patients on which estimates are based					
Grade 1 [†] N=15	39.3 [24.6-51.1]	63.1 [43.2-76.1]	77.6 [57.2-88.3]	86.4 [67.7-94.3]	91.8 [75.7-97.2]
Grade 2 [†] N=250	28 [24.1-31.7]	48.1 [42.3-53.4]	62.7 [56.2-68.1]	73.1 [66.8-78.2]	80.6 [74.8-85.1]
Grade 3, unilateral, age 0-24 N=27	21.4 [10.8-30.8]	38.2 [20.4-52.1]	51.5 [29.6-68.8]	61.9 [36.6-77.1]	70 [43.5-84.1]
Grade 3, unilateral, age 25-60 N=27	13.4 [4.6-21.4]	25 [8.9-38.3]	35.1 [13.1-51.5]	43.8 [17.1-61.9]	51.3 [20.9-70.1]
Grade 3, unilateral, age 61-120 N=15	10.8 [3.5-17.5]	20.5 [6.9-32]	29.1 [10.2-43.9]	36.7 [13.4-53.8]	43.6 [16.5-61.9]
Grade 3, bilateral, age 0-24 N=62	12.7 [7-18.1]	23.8 [13.5-32.9]	33.5 [19.5-45]	41.9 [25.1-55]	49.3 [30.3-63.1]
Grade 3, bilateral, age 25-60 N=53	7 [3.1-10.8]	13.5 [6.1-20.4]	19.6 [9-28.9]	25.2 [11.8-36.6]	30.5 [14.6-43.4]
Grade 3, bilateral, age 61-120 N=14	2.6 [0.7-4.5]	5.2 [1.4-8.8]	7.7 [2.1-13]	10.1 [2.8-16.9]	12.5 [3.5-20.7]
Grade 4, unilateral [‡] N=28	16.1 [8.5-23.1]	29.7 [16.4-40.8]	41 [23.5-54.5]	50.5 [30-65]	58.5 [36-73.1]
Grade 4, bilateral [‡] N=96	4.5 [1-7.9]	6.4 [2-15.1]	7.8 [3-21.8]	8.9 [4-28]	9.9 [4.9-33.7]

* The yearly rate of reflux resolution remains constant for each group
[†] No difference shown by age or laterality (unilateral/bilateral); therefore, these categories were combined
[‡] Estimates only apply to the time of diagnosis and are not age specific.

Important information about Deflux

Deflux® is indicated for treatment of vesicoureteral reflux in children. Children with certain medical conditions should not be treated with Deflux: primary refluxing megaureters with distal stenosis, uncontrolled voiding dysfunction. Discuss these conditions with your healthcare provider. There is a small risk of infection and bleeding from the procedure. Other adverse effects can happen. Some are rare blockages in the ureters. Discuss these adverse effects with your healthcare provider. For more information about Deflux, please visit deflux.com.
 G-Med AB is the current legal manufacturer and holds the CE Mark.

Palette Life Sciences Medical Information Department - EU

FR: +33 (0) 800 000 013
 DE: +49 (0) 800 1813 334
 IT: +39 800 785 440
 ES: +34 900 993 304
 UK: +44 (0) 823 4628
 e: palettemc@dlss.com

Visit Deflux.com for more information

References
 1. Kalkavaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesicoureteral reflux. *J Pediatr Urol.* 2012;29(4):359-365.
 2. Elder JS, Peters CA, Arant BS, et al. AUA pediatric vesicoureteral reflux clinical guidelines panel: The management of primary vesicoureteral reflux in children. *American Urological Association Education and Research, Inc.* 1997.